Second Gene Therapy from MeiraGTx Granted Rare Pediatric Disease Designation – Rare Disease Report
Rare Disease Report |
Second Gene Therapy from MeiraGTx Granted Rare Pediatric Disease Designation
Rare Disease Report This morning, the Offices of Orphan Products Development and Pediatric Therapeutics of the U.S. Food and Drug Administration (FDA) have granted rare pediatric disease designation to MeiraGTx's A002 (ZZV2/8-hCARp.hCNGB3). The gene therapy product … MeiraGTx Receives Rare Pediatric Disease Designation for A002 for the Treatment of Achromatopsia Due to Mutations … |
